Cargando…

2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics

BACKGROUND: Antibiotic overuse in LRTI is a major healthcare care problem, contributing to antimicrobial resistance. A novel assay that integrates blood levels of three immune-proteins TRAIL\IP-10\CRP was developed to assist in differentiating bacterial from viral disease. The assay exhibited high p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shani, Liran, Halabi, Salim, Shiber, Shachaf, Paz, Meital, Moscoviz, Einat, Neuberger, Ami, Petersiel, Neta, Grupper, Mordechai, Kirshner, Dani, Haber, Daniel, Kronenfeld, Gali, Samuel Mastboim, Niv, Gottlieb, Tanya, Stein, Michal, Rudich, Nurit, Sitry, Naama, Guetta, Claire S, Pri-or, Ester, Lishtzinsky, Ynon, Yanai, Shirly, Maor, Yasmin, Oved, Kfir, Eden, Eran, Drescher, Michael, Paul, Mical
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810701/
http://dx.doi.org/10.1093/ofid/ofz360.1902
_version_ 1783462311866925056
author Shani, Liran
Halabi, Salim
Shiber, Shachaf
Paz, Meital
Moscoviz, Einat
Neuberger, Ami
Petersiel, Neta
Grupper, Mordechai
Kirshner, Dani
Haber, Daniel
Kronenfeld, Gali
Samuel Mastboim, Niv
Gottlieb, Tanya
Stein, Michal
Rudich, Nurit
Sitry, Naama
Guetta, Claire S
Pri-or, Ester
Lishtzinsky, Ynon
Yanai, Shirly
Maor, Yasmin
Oved, Kfir
Eden, Eran
Drescher, Michael
Paul, Mical
author_facet Shani, Liran
Halabi, Salim
Shiber, Shachaf
Paz, Meital
Moscoviz, Einat
Neuberger, Ami
Petersiel, Neta
Grupper, Mordechai
Kirshner, Dani
Haber, Daniel
Kronenfeld, Gali
Samuel Mastboim, Niv
Gottlieb, Tanya
Stein, Michal
Rudich, Nurit
Sitry, Naama
Guetta, Claire S
Pri-or, Ester
Lishtzinsky, Ynon
Yanai, Shirly
Maor, Yasmin
Oved, Kfir
Eden, Eran
Drescher, Michael
Paul, Mical
author_sort Shani, Liran
collection PubMed
description BACKGROUND: Antibiotic overuse in LRTI is a major healthcare care problem, contributing to antimicrobial resistance. A novel assay that integrates blood levels of three immune-proteins TRAIL\IP-10\CRP was developed to assist in differentiating bacterial from viral disease. The assay exhibited high performance in blinded validation studies focusing on children. We performed a preliminary analysis of the ongoing OBSERVER study, evaluating the assay’s potential to reduce antibiotic misuse in adult patients presenting with suspicion of LRTI. METHODS: OBSERVER (NCT03011515) is an EU Horizon 2020 funded study (grant No. 684589), the first to validate the signature in adult LRTI patients. For every participant recruited at the emergency departments of three hospitals in Israel, we collected medical history, physical examination, routine lab, imaging, and respiratory multiplex PCR data. The assay outcomes are bacterial, viral or equivocal. Reference standard outcome of bacterial, viral, indeterminate or noninfectious, was assigned by expert panel majority adjudication. Indeterminates were excluded from the analysis. RESULTS: In this preliminary analysis, we included the first 218 patients with locked data (Figure 1). Age ranged from 18 to 96 years (mean 59.5). Clinical syndromes included: 21% pneumonia, 13% acute bronchitis, 6% COPD exacerbation, 32% upper respiratory tract infection and 16% unspecified LRTI or viral infections. The assay demonstrated high diagnostic performance for distinguishing bacterial from viral disease (Figure 2). Assay equivocal rate was 8%. In this cohort, antibiotics were prescribed to 41 of 105 patients with viral reference outcomes indicating an overuse rate of 39%, of these, 34 yielded viral index test outcomes, supporting the potential of the assay to reduce overuse by ~83%. CONCLUSION: The TRAIL/IP-10/CRP assay demonstrated high diagnostic performance for differentiating between bacterial and viral disease. Medical literature shows that there is a big gap between guidelines antibiotic prescription recommendations and reported prescribing rates (~25% vs. 40%-50%) for suspected LRTI in adults. The use of this new assay, which has a specificity of 93% and NPV of 99%, can help to close the gap and improve adherence to the guidelines. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810701
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68107012019-10-28 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics Shani, Liran Halabi, Salim Shiber, Shachaf Paz, Meital Moscoviz, Einat Neuberger, Ami Petersiel, Neta Grupper, Mordechai Kirshner, Dani Haber, Daniel Kronenfeld, Gali Samuel Mastboim, Niv Gottlieb, Tanya Stein, Michal Rudich, Nurit Sitry, Naama Guetta, Claire S Pri-or, Ester Lishtzinsky, Ynon Yanai, Shirly Maor, Yasmin Oved, Kfir Eden, Eran Drescher, Michael Paul, Mical Open Forum Infect Dis Abstracts BACKGROUND: Antibiotic overuse in LRTI is a major healthcare care problem, contributing to antimicrobial resistance. A novel assay that integrates blood levels of three immune-proteins TRAIL\IP-10\CRP was developed to assist in differentiating bacterial from viral disease. The assay exhibited high performance in blinded validation studies focusing on children. We performed a preliminary analysis of the ongoing OBSERVER study, evaluating the assay’s potential to reduce antibiotic misuse in adult patients presenting with suspicion of LRTI. METHODS: OBSERVER (NCT03011515) is an EU Horizon 2020 funded study (grant No. 684589), the first to validate the signature in adult LRTI patients. For every participant recruited at the emergency departments of three hospitals in Israel, we collected medical history, physical examination, routine lab, imaging, and respiratory multiplex PCR data. The assay outcomes are bacterial, viral or equivocal. Reference standard outcome of bacterial, viral, indeterminate or noninfectious, was assigned by expert panel majority adjudication. Indeterminates were excluded from the analysis. RESULTS: In this preliminary analysis, we included the first 218 patients with locked data (Figure 1). Age ranged from 18 to 96 years (mean 59.5). Clinical syndromes included: 21% pneumonia, 13% acute bronchitis, 6% COPD exacerbation, 32% upper respiratory tract infection and 16% unspecified LRTI or viral infections. The assay demonstrated high diagnostic performance for distinguishing bacterial from viral disease (Figure 2). Assay equivocal rate was 8%. In this cohort, antibiotics were prescribed to 41 of 105 patients with viral reference outcomes indicating an overuse rate of 39%, of these, 34 yielded viral index test outcomes, supporting the potential of the assay to reduce overuse by ~83%. CONCLUSION: The TRAIL/IP-10/CRP assay demonstrated high diagnostic performance for differentiating between bacterial and viral disease. Medical literature shows that there is a big gap between guidelines antibiotic prescription recommendations and reported prescribing rates (~25% vs. 40%-50%) for suspected LRTI in adults. The use of this new assay, which has a specificity of 93% and NPV of 99%, can help to close the gap and improve adherence to the guidelines. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810701/ http://dx.doi.org/10.1093/ofid/ofz360.1902 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Shani, Liran
Halabi, Salim
Shiber, Shachaf
Paz, Meital
Moscoviz, Einat
Neuberger, Ami
Petersiel, Neta
Grupper, Mordechai
Kirshner, Dani
Haber, Daniel
Kronenfeld, Gali
Samuel Mastboim, Niv
Gottlieb, Tanya
Stein, Michal
Rudich, Nurit
Sitry, Naama
Guetta, Claire S
Pri-or, Ester
Lishtzinsky, Ynon
Yanai, Shirly
Maor, Yasmin
Oved, Kfir
Eden, Eran
Drescher, Michael
Paul, Mical
2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title_full 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title_fullStr 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title_full_unstemmed 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title_short 2224. Reducing Antibiotic Overuse in Adult Lower Respiratory Tract Infections Using Novel Host–Response-Based Diagnostics
title_sort 2224. reducing antibiotic overuse in adult lower respiratory tract infections using novel host–response-based diagnostics
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810701/
http://dx.doi.org/10.1093/ofid/ofz360.1902
work_keys_str_mv AT shaniliran 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT halabisalim 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT shibershachaf 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT pazmeital 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT moscovizeinat 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT neubergerami 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT petersielneta 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT gruppermordechai 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT kirshnerdani 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT haberdaniel 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT kronenfeldgali 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT samuelmastboimniv 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT gottliebtanya 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT steinmichal 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT rudichnurit 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT sitrynaama 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT guettaclaires 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT priorester 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT lishtzinskyynon 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT yanaishirly 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT maoryasmin 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT ovedkfir 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT edeneran 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT dreschermichael 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics
AT paulmical 2224reducingantibioticoveruseinadultlowerrespiratorytractinfectionsusingnovelhostresponsebaseddiagnostics